Abstracts tagged "Early Rheumatoid Arthritis"

Abstract Number: 0812 • ACR Convergence 2021
Are Biologic and Targeted Synthetic Disease Modifying Anti-Rheumatic Drugs Associated with Work Participation Improvement in Early Rheumatoid Arthritis? A Systematic Review and Meta-analysis
Mary Lucy Marques¹, Alessia Alunno², Louise Falzon³, Annelies Boonen⁴ and Sofia Ramiro¹, ¹Leiden University Medical Center, Leiden, Netherlands, ²University of Perugia, Perugia, Italy, ³Center for Personalized Health, Northwell Health, New York City, NY, ⁴Department of Internal Medicine, Division of Rheumatology, Maastricht University Medical Centre+ (MUMC+), Maastricht, Limburg, Netherlands
Background/Purpose: Treatment of early RA with DMARDs is associated with particularly effective responses, resulting in sustained beneficial outcomes, including clinical and radiographic remission and optimal…
Abstract Number: L07 • 2019 ACR/ARP Annual Meeting
A Serum Proteomic Signature Defines Transition from the Preclinical State to Rheumatoid Arthritis
Liam O'Neil¹, Victor Spicer ¹, Irene Smolik ¹, Xiaobo Meng ¹, John Wilkins ¹ and Hani El-Gabalawy ², ¹University of Manitoba, Winnipeg, Canada, ²University of Manitoba, Winnipeg, MB, Canada
Background/Purpose: Anti-citrullinated protein antibodies (ACPA) are currently the primary biomarker for identifying individuals at increased risk for future RA development. However, we have recently shown…
Abstract Number: 451 • 2019 ACR/ARP Annual Meeting
Persistent and Non-Articular Regional and Widespread Pain Are Common in Early Rheumatoid Arthritis, Impacting Remission Rates and Reflected in Patient Global Scores
Vivian P. Bykerk¹, Orit Schieir ², Marie-France Valois ³, Gilles Boire ⁴, Glen Hazlewood ⁵, Louis Bessette ⁶, Carol Hitchon ⁷, Diane Tin ⁸, Carter Thorne ⁹, Edward Keystone ¹⁰, Janet Pope ¹¹, Susan J. Bartlett ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹Hospital for Special Surgery, New York, NY, ²University of Toronto Dalla Lana School of Public Health, Toronto, ON, Canada, ³McGill University, Montreal, Canada, ⁴Sherbrooke University, Sherbrooke, QC, Canada, ⁵University of Calgary, Calgary, AB, Canada, ⁶Laval University, Quebec City, QC, Canada, ⁷University of Manitoba, Winnipeg, Canada, ⁸Southlake Regional Health Centre, Newmarket, Canada, ⁹Southlake Regional Health Centre, Newmarket, ON, Canada, ¹⁰Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹¹Western University, London, ON, Canada, ¹²McGill University, Montreal, QC, Canada, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Persisting pain (NRS ≥4,) (PP) and non-articular pain (NAP), reduces quality of life for patients with RA. NAP is often attributed to fibromyalgia (FM),…
Abstract Number: 1406 • 2019 ACR/ARP Annual Meeting
Impact on Costs and Quality of Life over 5 Years of Treat-to-target Treatment Strategies Initiating Tocilizumab, Methotrexate or Their Combination in Early Rheumatoid Arthritis: Economic Evaluation of the U-Act-Early Trial
Maxime Verhoeven¹, Janneke Tekstra ¹, Attila Pethö-Schramm ², Michelle Borm ³, Jacob van Laar ¹, Floris Lafeber ¹, Johannes Bijlsma ¹, Johannes Jacobs ¹ and Paco Welsing ¹, ¹UMC Utrecht, Department of Rheumatology & Clinical Immunology, Utrecht, The Netherlands, Utrecht, Netherlands, ²Hoffmann-La Roche, Basel, Basel, Switzerland, ³Roche Nederland BV, Woerden, Netherlands
Background/Purpose: U-Act-Early was a 2-year multicentre, double-blind, randomized, placebo-controlled trial in early (DMARD-naïve) RA patients treated to the target of remission. Patients were assigned to…
Abstract Number: 2846 • 2019 ACR/ARP Annual Meeting
Outcomes over the First 5 Years of Follow up in a Very Early Rheumatoid Arthritis (RA) Cohort Recruited over 20 Years: Most of the Improvement Occurred Before the 2011 Implementation of Treat-to-Target (T2T)
Nathalie Carrier ¹, Sophie Roux ², Ariel Masetto ², Artur deBrum Fernandes ², Patrick Liang ², Meryem Maoui ³ and Gilles Boire², ¹CIUSSS de l'Estrie-CHUS, Sherbrooke, QC, Canada, ²Université de Sherbrooke, Sherbrooke, QC, Canada, ³Bristol-Myers Squibb Canada, St-Laurent, QC, Canada
Background/Purpose: To analyze the evolution over 20 years of disease activity, treatments and radiographic progression over the first 5 years of follow up of patients…
Abstract Number: 460 • 2019 ACR/ARP Annual Meeting
Fertility of Women with Rheumatoid Arthritis: Disease Activity Negatively Correlates with Serum AMH Levels
Camille Valdeyron¹, Martin SOUBRIER ², Bruno Pereira ¹, Arnaud Constantin ³, Jacques Morel ⁴, Philippe Gaudin ⁵, Bernard Combe ⁶ and Florence Brugnon ¹, ¹CHU CLERMONT-FERRAND, Clermont-Ferrand, France, ²CHU Gabriel Montpied, Clermont Ferrand, Auvergne, France, ³CHU TOUOUSE, TOULOUSE, France, ⁴CHU MONTPELLIER, MONTPELLIER, France, ⁵Rheumatology Department, CHU Grenoble Alpes Hôpital Sud and GREPI - Université Grenoble Alpes, EA7408, Grenoble - Echirolles, France, ⁶CHU Montpellier, Montpellier University, Montpellier, France
Background/Purpose: Patients with rheumatoid arthritis (RA) display a higher infertility prevalence compared with the general population. Disease-related inflammation and RA treatments are likely to be…
Abstract Number: 1413 • 2019 ACR/ARP Annual Meeting
Efficacy of Tofacitinib Monotherapy, Tofacitinib with Methotrexate and Adalimumab with Methotrexate in Patients with Early ( ≤ 2 Years) vs Established ( > 2 Years) Rheumatoid Arthritis: A Post Hoc Analysis of Data from ORAL Strategy
Tsutomu Takeuchi¹, Yoshiya Tanaka ², Naonobu Sugiyama ³, Noriko Iikuni ⁴, Koshika Soma ⁵, Harry Shi ⁶, Eduardo Mysler ⁷, Robert J. Moots ⁸, Josef Smolen ⁹ and Roy Fleischmann ¹⁰, ¹Division of Rheumatology, Department of Internal Medicine, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan, ²University of Occupational and Environmental Health Japan, Kitakyushu, Japan, ³Pfizer Japan Inc, Tokyo, Japan, ⁴Pfizer Inc, New York, NY, ⁵Pfizer Inc, Groton, CT, ⁶Pfizer Inc, Collegeville, PA, ⁷Organización Médica de Investigación, Buenos Aires, Argentina, ⁸Institute of Ageing and Chronic Disease, Liverpool, United Kingdom, ⁹Medical University of Vienna, Vienna, Austria, ¹⁰Metroplex Clinical Research Center and University of Texas Southwestern Medical Center, Dallas, TX
Background/Purpose: Tofacitinib is an oral JAK inhibitor for the treatment of RA. Greater improvements in efficacy outcomes have been reported with tofacitinib 5 mg BID ±…
Abstract Number: 2851 • 2019 ACR/ARP Annual Meeting
Limiting Factors of Reaching ACR/EULAR Boolean Remission in Early RA Patients Treated According to Current Recommendations
Nina Sundlisater¹, Anna-Birgitte Aga ², Ulf Sundin ³, Hilde Hammer ¹, Till Uhlig ⁴, Tore Kvien ⁴, Espen Haavardsholm ⁴ and Siri Lillegraven ⁵, ¹Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ³Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway. University of Oslo, Oslo, Norway, Oslo, Oslo, Norway, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁵Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway
Background/Purpose: Abrogation of inflammation is important to prevent irreversible joint damage and maximize health-related quality of life in early RA patients. The ACR/EULAR Boolean remission…
Abstract Number: 470 • 2019 ACR/ARP Annual Meeting
Obesity Is a Robust Predictor of Persistent High Fatigue at 1 Year in Women and Men with Early Rheumatoid Arthritis
Susan J. Bartlett¹, Orit Schieir ², Marie-France Valois ³, Janet Pope ⁴, Louis Bessette ⁵, Carol Hitchon ⁶, Carter Thorne ⁷, Diane Tin ⁸, Glen Hazlewood ⁹, Gilles Boire ¹⁰, Edward Keystone ¹¹, Vivian Bykerk ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹McGill University, Montreal, QC, Canada, ²University of Toronto, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴Western University, London, ON, Canada, ⁵Laval University, Quebec City, QC, Canada, ⁶University of Manitoba, Winnipeg, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Southlake Regional Health Centre, Newmarket, Canada, ⁹University of Calgary, Calgary, Canada, ¹⁰Sherbrooke University, Sherbrooke, QC, Canada, ¹¹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York City, NY, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: While treat-to-target strategies can dramatically reduce inflammation in RA, persistently high levels of fatigue are present in many patients and represent an important unmet need.…
Abstract Number: 1859 • 2019 ACR/ARP Annual Meeting
Joint Tenderness and Ultrasound Inflammation in DMARD-naïve Early Rheumatoid Arthritis Patients
Nina Sundlisater¹, Anna-Birgitte Aga ², Hilde Hammer ¹, Till Uhlig ³, Tore Kvien ³, Espen Haavardsholm ³ and Siri Lillegraven ⁴, ¹Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Norway, ²Diakonhjemmet Hospital, Department of Rheumatology, Oslo, Oslo, Norway, ³Diakonhjemmet Hospital, Dept. of Rheumatology / University of Oslo, Faculty of Medicine, Oslo, Norway, ⁴Diakonhjemmet Hospital, Dept. of Rheumatology, Oslo, Norway
Background/Purpose: A tender joint count is part of most disease activity scores and remission criteria in rheumatoid arthritis (RA). A recent study in established RA…
Abstract Number: 2870 • 2019 ACR/ARP Annual Meeting
Persistence of B Cell-rich Synovitis Following Conventional Synthetic Disease Modifying Anti-Rheumatic Drug Treatment in Early Rheumatoid Arthritis Is Associated with Radiographic Progression Independently of Clinical Response
Felice Rivellese¹, Gloria Lliso-Ribera ², Alessandra Nerviani ¹, Frances humby ³ and Costantino Pitzalis ¹, ¹Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, United Kingdom, ²Centre for Experimental Medicine & Rheumatology, Queen Mary University of London, London, ³Queen Mary University of London, London, United Kingdom
Background/Purpose: Synovial B cell aggregates in patients with early Rheumatoid Arthritis (RA) have been associated with disease severity and radiographic progression. Here, we analysed the…
Abstract Number: 471 • 2019 ACR/ARP Annual Meeting
When Will I Get past This Exhaustion? Predictors of Improved Fatigue in the First Year of RA
Susan J. Bartlett¹, Orit Schieir ², Marie-France Valois ³, Carol Hitchon ⁴, Louis Bessette ⁵, Glen Hazlewood ⁶, Carter Thorne ⁷, Janet Pope ⁸, Gilles Boire ⁹, Diane Tin ¹⁰, Edward Keystone ¹¹, Vivian Bykerk ¹² and Canadian Early Arthritis Cohort (CATCH) Investigators ¹³, ¹McGill University, Montreal, QC, Canada, ²University of Toronto, Montreal, Canada, ³McGill University, Montreal, Canada, ⁴University of Manitoba, Winnipeg, Canada, ⁵Laval University, Quebec City, QC, Canada, ⁶University of Calgary, Calgary, Canada, ⁷Southlake Regional Health Centre, Newmarket, ON, Canada, ⁸Western University, London, ON, Canada, ⁹Sherbrooke University, Sherbrooke, QC, Canada, ¹⁰Southlake Regional Health Centre, Newmarket, Canada, ¹¹Mount Sinai Hospital and University of Toronto, Toronto, ON, Canada, ¹²Hospital for Special Surgery, New York City, NY, ¹³Canadian Early Arthritis Cohort (CATCH) Study, Toronto, Canada
Background/Purpose: Although overwhelming fatigue is common at the onset of RA, some patients continue to experience debilitating high levels of fatigue that impact mood, interfere with work…
Abstract Number: 1885 • 2019 ACR/ARP Annual Meeting
A Search to the Target Tissue in Which RA-specific Inflammation Starts: A Detailed MRI Study to Improve Identification of RA-specific Features in the Phase of Clinically Suspect Arthralgia
Xanthe ME Matthijssen¹, Fenne Wouters ², Debbie Boeters ², Aleid Boer ², Yousra Dakkak ², Ellis Niemantsverdriet ² and Annette van der Helm-van Mil ³, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: Based on a unique cohort of clinically suspect arthralgia (CSA) patients, we analysed which combinations of MRI-features at onset were predictive for Rheumatoid Arthritis…
Abstract Number: 2871 • 2019 ACR/ARP Annual Meeting
Advances in Treatment of Rheumatoid Arthritis: ACPA-positive Patients Benefited More Than ACPA-negative Patients; 25 Year Results of a Longitudinal Cohort Study
Xanthe ME Matthijssen¹, Ellis Niemantsverdriet ², Thomas Huizinga ² and Annette van der Helm-van Mil ³, ¹Department of Rheumatology, Leiden University Medical Center, Leiden, The Netherlands, Leiden, Netherlands, ²Leiden University Medical Center, Leiden, Netherlands, ³LUMC, Leiden, Zuid-Holland, Netherlands
Background/Purpose: The last 25 years, treatment of rheumatoid arthritis (RA) has changed considerably. Although clinically relevant joint damage has become infrequent, it is less established…
Abstract Number: 479 • 2019 ACR/ARP Annual Meeting
Impact of Achieving Early-sustained Remission on Preventing Long-term Functional Loss in Patients with Early Rheumatoid Arthritis
Evelyn Chow¹, Isaac T. Cheng ¹, Lai-Shan Tam ¹ and CRYSTAL Study Team Hong Kong ², ¹The Chinese University of Hong Kong, Hong Kong, Hong Kong, ²The Chinese University of Hong Kong, Hong Kong
Background/Purpose: Preventing functional loss is crucial to early RA (ERA) patients in order to maintain usual activities of daily living. However, whether achieving early and…

1
2
3
…
18
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].